Cognoa logo.

Cognoa Seeks FDA Clearance for Breakthrough Digital Autism Diagnostic Device After Successful Pivotal Study

Cognoa’s autism diagnostic device is positioned to be the first FDA-cleared digital solution enabling pediatricians to diagnose autism – a paradigm shift in the standard of care (Palo Alto, Calif. – September 23, 2020) – Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, announced today that…

How AI can overcome gender bias in autism diagnosis and treatment

Researchers and advocates have convincingly shown that the wide gap in diagnoses between boys and girls isn’t simply a matter of boys being significantly more likely to be on the autism spectrum. By DAVID HAPPEL Statistically, boys are four times as likely as girls to receive a diagnosis of autism spectrum disorder (ASD). But that’s not because boys are four times as likely to have ASD. According…

Cognoa Appoints Industry Leader David Happel as New Chief Executive Officer

Happel takes up the top job at Cognoa after over 25 years of successfully commercializing medical products and as a leader in the biotech and biopharma industries.  (Palo Alto, Calif. – March 24, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today the appointment of David Happel as Chief Executive Officer. Cognoa’s former CEO…

Can AI Help With Autism Diagnosis?

An Interview with Cognoa’s CEO Brent Vaughan In the US, one in five children are living with a diagnosable behavioral health disorder; however, only 21% of those children who are diagnosed receive needed treatment. Often, parents have to wait one to three years to receive a proper and accurate diagnosis, and an individualized treatment plan for their child. For the last 15 years, the average…

Cognoa Appoints Dr. Colleen Kraft Senior Medical Director of Clinical Adoption

AAP 2018 Past President Joins Cognoa to Improve the Standard of Care for Children with Autism Through Greater Pediatrician Adoption of Digital Prescription Apps (Palo Alto, Calif.– March 5, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that renowned pediatrician and 2018 Past President of the American Academy of Pediatrics (AAP), Dr. Colleen…

This shows a photo of Brent Vaughan CEO of Cognoa.

Cognoa CEO to Participate in the Cowen and Company 40th Annual Healthcare Conference

PALO ALTO, Calif. — February 26, 2020 — Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that CEO, Brent Vaughan, will participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference with executives from Akili Interactive Labs, Click Therapeutics and Pear Therapeutics. The panel will take place at 1:30…

Logo for Autism Learning Partners who Cognoa is partnered with.

Autism Learning Partners and Cognoa Announce Partnership to Enable Earlier Access to Care

PASADENA and PALO ALTO, Calif. – February 11, 2020 –  Autism Learning Partners (“ALP”), a national leader in the treatment of autism and other developmental disabilities, and Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today a partnership designed to accelerate the diagnosis of autism to enable interventions earlier, when there is the greatest potential to…

Location

Social